{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T18:50:54Z","timestamp":1648839054790},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1684\/bdc.2013.1877","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:58:43Z","timestamp":1565726323000},"page":"68-74","source":"Crossref","is-referenced-by-count":0,"title":["Actualit\u00e9s th\u00e9rapeutiques dans le lymphome hodgkinien classique"],"prefix":"10.1016","volume":"101","author":[{"given":"Pauline","family":"Brice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2013.1877_bib0005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(03)12777-8","article-title":"Hodgkin's lymphoma","volume":"361","author":"Yung","year":"2003","journal-title":"Lancet"},{"key":"10.1684\/bdc.2013.1877_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/modpathol.3880035","article-title":"The WHO classification of hematological malignancies, report of the clinical advisory committee meeting","volume":"13","author":"Harris","year":"2000","journal-title":"Mod Pathol"},{"key":"10.1684\/bdc.2013.1877_bib0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00330-006-0393-0","article-title":"Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas","volume":"17","author":"De Kerviler","year":"2007","journal-title":"Eur Radiol"},{"key":"10.1684\/bdc.2013.1877_bib0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0025","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography\/Computed Tomography-Staged Treatment-Naive Patients With Hodgkin Lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0030","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim2 FDG PET is prognostically superior to IPS score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1684\/bdc.2013.1877_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/annonc\/11.suppl_1.S81","article-title":"Treatment of Hodgkin's disease: results and curent concepts of the German Hodgkin's Lymphoma Study Group","volume":"11","author":"Sieber","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0040","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early stage Hodgkin's disease","volume":"357","author":"Ferme","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1684\/bdc.2013.1877_bib0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0050","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"Boll","year":"2011","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1877_bib0055","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study","volume":"28","author":"Mauz-Korholz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0060","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"(2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"JClin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"(2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"JClin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1877_bib0075","doi-asserted-by":"crossref","unstructured":"Carde P, Karrasch M, Fortpied C, et al. ABVD (8 cycles) vs BEACOPP (4escalated cycles => 4 baseline) in stage III-IV high risk Hodgkin Lymphoma (HL): first results of EORTC Intergroup 2012 study. ASCO 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.8002"},{"key":"10.1684\/bdc.2013.1877_bib0080","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1684\/bdc.2013.1877_bib0085","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2001.19.11.2905","article-title":"Low dose radiation therapy is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease","volume":"19","author":"D\u00fchmke","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0090","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1684\/bdc.2013.1877_bib0095","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/cncr.24178","article-title":"(2009) Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8consecutive rials","volume":"115","author":"Favier","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1684\/bdc.2013.1877_bib0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1877_bib0105","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 M, Reman O, Federico M, et al. Interim analysis of the randomized EORTC\/LYSA\/FIL Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I\/II Hodgkin lymphoma. Blood(ASH Annual Meeting Abstracts) 2012; 120: Abstract 549.","DOI":"10.1182\/blood.V120.21.549.549"},{"key":"10.1684\/bdc.2013.1877_bib0110","doi-asserted-by":"crossref","unstructured":"Radford J, O\u2019Doherty M, Barrington S, et al. Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A HodgkinLymphoma and a \u2018negative\u2019 FDG-PET Scan after 3 Cycles ABVD. Blood(ASH Annual Meeting Abstracts) 2008; 112: Abstract 369.","DOI":"10.1182\/blood.V112.11.369.369"},{"key":"10.1684\/bdc.2013.1877_bib0115","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved field radiotherapy for advanced Hodgkin lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1877_bib0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.06998.x","article-title":"Managing relapsed and refractory Hodgkin lymphoma","volume":"141","author":"Brice","year":"2008","journal-title":"B J Haematol"},{"key":"10.1684\/bdc.2013.1877_bib0125","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensify chemotherapy in patients with relapsed Hodgkin's lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0130","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalisation of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves EFS in patients with HL","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1877_bib0135","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or double autologous stem-cell transplantation for first relapsing\/refractory Hodgkin lymphoma: results of the prospective multicenter H96 trial","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"RIC conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma, an analysis from the lymphoma working party of the EBMT","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1877_bib0145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after RIC in patients with relapsed and refractory HL","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2013.1877_bib0150","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of HL patients relapsing after autologous transplantation","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1877_bib0155","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1684\/bdc.2013.1877_bib0160","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.12428","article-title":"Pegylated liposomal doxorubicin is an efficient treatment in patients with hodgkin lymphoma relapsing after high dose therapy and stem cell transplation","volume":"162","author":"Clozel","year":"2013","journal-title":"Brit J Haematol"},{"issue":"5","key":"10.1684\/bdc.2013.1877_bib0165","first-page":"544","article-title":"Clinical experience of bendamustine in relapsed or refractory Hodgkin Lymphoma: a retrospective analysis of the French compassionate use program in 28 patients","volume":"96","author":"Ghesquieres","year":"2012","journal-title":"Leukemia & Lymphoma"},{"key":"10.1684\/bdc.2013.1877_bib0170","doi-asserted-by":"crossref","unstructured":"Younes A, Gopal AK, Smith Se, et al (2012). Results of a pivotal phase II study of Brentuximab vedotin for relapsed or refractory Hodgkin's Lymphoma. J Clin Oncol 2012, published on line March 26.","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"10.1684\/bdc.2013.1877_bib0175","first-page":"666","article-title":"Gu\u00e9ri d\u2019une maladie de Hodgkin","volume":"89","author":"Brice","year":"2002","journal-title":"Bull Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:23:54Z","timestamp":1602491034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115301533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0007455115301533"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2013.1877","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}